Eli Lilly expanded its AI drug discovery collaboration with Insilico Medicine, signing a deal that could total $2.75 billion in development, regulatory, and commercial milestones. Lilly will pay $115 million upfront, and the partners will develop and commercialize preclinical oral therapeutics across multiple therapeutic areas, according to deal terms disclosed by Insilico and Lilly. Insilico’s leadership said the expanded partnership leverages Lilly’s clinical development depth and disease expertise while applying Insilico’s AI discovery capabilities. The collaboration follows earlier licensing access to Insilico’s Pharma.AI software suite and a prior agreement to deepen the companies’ joint discovery and development workflow. The announcement places Lilly among the biggest adopters of AI-enabled discovery at scale, with Insilico reporting a pipeline that spans cancer, idiopathic pulmonary fibrosis, inflammatory bowel disease, metabolic disease programs, and inflammation. For the biotech industry, the transaction highlights a shift from point solutions toward commercialization-oriented AI partnerships that can translate discovery outputs into clinical candidates and future product revenue.